person · Reporting owner

Culverwell Anthony James

Disclosed activity across 2 companies

Tapewire entity: 17951
SEC CIK: 0001693548

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Quoin Pharmaceuticals Ltd.QNRX · Entity 7876	Director	August 31, 2026	September 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Quoin Pharmaceuticals Ltd.

Report date August 31, 2026 · Filed September 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
ADSsSEC Table I · non-derivative	Direct	40,364	Reported balance After 2026-08-31 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-08-31 · Purchase · Acquired 6,146 · Balance 40,364 F1: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer. F2: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.
Ordinary Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.10	Direct	3,073	Reported balance After 2026-08-31 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-08-31 · Purchase · Acquired 3,073 · Balance 3,073 F2: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88. F3: The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap. F4: The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome. F1: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

F2: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

F3: The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

F4: The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Innocoll Holdings plc

Report date July 24, 2017 · Filed July 26, 2017

Section 16 reporting ended · disclosed 2017-07-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary Shares, par value $0.01 per shareSEC Table I · non-derivative	Direct	Reported balance After 2017-07-24 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2017-07-24 · Disposition to issuer · Disposed 291,566 · Balance 0 F1: Immediately prior to the Effective Time (as defined below), the Reporting Person beneficially owned 291,566 ordinary shares of the Issuer, par value $0.01 per share ("Ordinary Shares"). F2: Pursuant to the terms of the Transaction Agreement by and among the Issuer, Gurnet Point L.P., a Delaware limited partnership acting through its general partner Waypoint International GP LLC ("Gurnet Point"), and Lough Ree Technologies Limited, an Irish private limited company and wholly-owned subsidiary of Gurnet Point (the "Transaction Agreement"), each Ordinary Share that was beneficially owned by the Reporting Person immediately prior to the effective time of the scheme (the "Effective Time") now represents the right to receive (i) $1.75 in cash and (ii) a contingent value right which represents a contractual right to receive payments up to a maximum aggregate amount of $4.90 in cash upon, and subject to, the occurrence of certain events, without interest and net of applicable tax withholdings.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.80 · Expires 2026-03-30	Direct	Reported balance After 2017-07-24 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-07-24 · Disposition to issuer · Disposed 11,659 · Balance 0 F3: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.80 · Expires 2026-03-30	Direct	Reported balance After 2017-07-24 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-07-24 · Disposition to issuer · Disposed 8,230 · Balance 0 F3: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.80 · Expires 2026-03-30	Direct	Reported balance After 2017-07-24 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-07-24 · Disposition to issuer · Disposed 14,907 · Balance 0 F3: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof.
WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $7.00 · Expires 2019-06-15	Direct	Reported balance After 2017-07-24 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-07-24 · Disposition to issuer · Disposed 57,240 · Balance 0 F4: Immediately prior to the Effective Time, the Reporting Person beneficially owned a warrant to purchase up to 57,240 Ordinary Shares (the "Warrant"). Pursuant to the terms of an Irrevocable Undertaking executed by the Reporting Person in connection with the Transaction Agreement, immediately prior to the Effective Time, the Warrant was terminated without any consideration being payable in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: Immediately prior to the Effective Time (as defined below), the Reporting Person beneficially owned 291,566 ordinary shares of the Issuer, par value $0.01 per share ("Ordinary Shares").

F2: Pursuant to the terms of the Transaction Agreement by and among the Issuer, Gurnet Point L.P., a Delaware limited partnership acting through its general partner Waypoint International GP LLC ("Gurnet Point"), and Lough Ree Technologies Limited, an Irish private limited company and wholly-owned subsidiary of Gurnet Point (the "Transaction Agreement"), each Ordinary Share that was beneficially owned by the Reporting Person immediately prior to the effective time of the scheme (the "Effective Time") now represents the right to receive (i) $1.75 in cash and (ii) a contingent value right which represents a contractual right to receive payments up to a maximum aggregate amount of $4.90 in cash upon, and subject to, the occurrence of certain events, without interest and net of applicable tax withholdings.

F3: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof.

F4: Immediately prior to the Effective Time, the Reporting Person beneficially owned a warrant to purchase up to 57,240 Ordinary Shares (the "Warrant"). Pursuant to the terms of an Irrevocable Undertaking executed by the Reporting Person in connection with the Transaction Agreement, immediately prior to the Effective Time, the Warrant was terminated without any consideration being payable in respect thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 31, 2026 Filed Sep 2, 2026 01:38 UTC	Quoin Pharmaceuticals Ltd. QNRX · Entity 7876	PurchaseOrdinary Warrants (Right to Buy) · Derivative	3,073	Not disclosed Strike: $6.10	Not disclosed	Disclosure SEC source: 0001104659-26-104402 · tm2624615-1_4seq1.xml · derivative · entry 2 Culverwell Anthony James · CIK 0001693548 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,073 Underlying: ADS · 3,073 shares Expires not disclosed F2 · kind: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88. F2 · price: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88. F3 · derivative.exercise_date: The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap. F4 · derivative.expiration_date: The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome. F1 · derivative.underlying: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer. Read SEC document
August 31, 2026 Filed Sep 2, 2026 01:38 UTC	Quoin Pharmaceuticals Ltd. QNRX · Entity 7876	PurchaseADSs	6,146	$4.88	$29,992.48	Disclosure SEC source: 0001104659-26-104402 · tm2624615-1_4seq1.xml · nonDerivative · entry 1 Culverwell Anthony James · CIK 0001693548 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,364 F1 · security: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer. F2 · kind: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88. Read SEC document
August 27, 2026 Filed Aug 28, 2026 22:39 UTC	Quoin Pharmaceuticals Ltd. QNRX · Entity 7876	GrantADSs	31,352	$5.15	$161,462.80	Disclosure SEC source: 0001104659-26-103374 · tm2624320-1_4seq1.xml · nonDerivative · entry 1 Culverwell Anthony James · CIK 0001693548 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,218 F1 · security: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer. F2 · kind: On August 27, 2026, the Issuer and the Reporting Person, entered into an exchange agreement, pursuant to which $161,461 of accrued interest outstanding ("Outstanding Debt") owed in connection with a note previously purchased by the Reporting Person was exchanged for 31,352 ADSs. The exchange agreement and the exchange of the Outstanding Debt for the ADSs was approved in advance by the Issuer's audit committee and board of directors. Read SEC document
February 04, 2026 Filed Feb 6, 2026 22:20 UTC	Quoin Pharmaceuticals Ltd. QNRX · Entity 7876	GrantShare Option (Right to Buy) · Derivative	21,709	$0.00 Strike: $7.37	$0.00	Disclosure SEC source: 0001104659-26-011617 · tm265448-6_4seq1.xml · derivative · entry 1 Culverwell Anthony James · CIK 0001693548 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,709 Underlying: ADS · 21,709 shares Expires 2036-02-04 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. Read SEC document
August 21, 2025 Filed Aug 25, 2025 20:05 UTC	Quoin Pharmaceuticals Ltd. QNRX · Entity 7876	GrantShare Option (Right to Buy) · Derivative	13,682	$0.00 Strike: $9.07	$0.00	Disclosure SEC source: 0001104659-25-082515 · tm2524172-2_4seq1.xml · derivative · entry 1 Culverwell Anthony James · CIK 0001693548 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,682 Underlying: ADS · 13,682 shares Expires 2035-05-28 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F2 · date: The option grant was approved by the Compensation Committee and the Board on May 29, 2025, subject to shareholder approval. The Company's shareholder's approved this option grant on August 21, 2025. F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F3 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029. F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. Read SEC document
May 29, 2025 Filed Jun 3, 2025 20:00 UTC	Quoin Pharmaceuticals Ltd. QNRX · Entity 7876	GrantShare Option (Right to Buy) · Derivative	7,760	$0.00 Strike: $9.07	$0.00	Disclosure SEC source: 0001104659-25-055943 · tm2516320-4_4seq1.xml · derivative · entry 1 Culverwell Anthony James · CIK 0001693548 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,760 Underlying: ADS · 7,760 shares Expires 2035-05-29 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029. F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. Read SEC document
December 23, 2024 Filed Dec 27, 2024 22:15 UTC	Quoin Pharmaceuticals Ltd. QNRX · Entity 7876	PurchaseSeries G Warrants (right to buy) · Derivative	100,000	Not disclosed Strike: $0.45	Not disclosed	Disclosure SEC source: 0001104659-24-132185 · tm2431988-1_4seq1.xml · derivative · entry 3 Culverwell Anthony James · CIK 0001693548 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: ADS · 100,000 shares Expires 2029-12-24 F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." F2 · price: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." F3 · derivative.exercise_date: The Warrants were exercisable immediately, subject to a beneficial ownership cap. Read SEC document
December 23, 2024 Filed Dec 27, 2024 22:15 UTC	Quoin Pharmaceuticals Ltd. QNRX · Entity 7876	PurchaseSeries F Warrants (right to buy) · Derivative	100,000	Not disclosed Strike: $0.45	Not disclosed	Disclosure SEC source: 0001104659-24-132185 · tm2431988-1_4seq1.xml · derivative · entry 2 Culverwell Anthony James · CIK 0001693548 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: ADS · 100,000 shares Expires 2026-12-23 F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." F2 · price: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." F3 · derivative.exercise_date: The Warrants were exercisable immediately, subject to a beneficial ownership cap. Read SEC document
December 23, 2024 Filed Dec 27, 2024 22:15 UTC	Quoin Pharmaceuticals Ltd. QNRX · Entity 7876	PurchaseOrdinary Shares	100,000	$0.45	$45,000.00	Disclosure SEC source: 0001104659-24-132185 · tm2431988-1_4seq1.xml · nonDerivative · entry 1 Culverwell Anthony James · CIK 0001693548 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,317 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants." Read SEC document
December 09, 2024 Filed Dec 10, 2024 21:50 UTC	Quoin Pharmaceuticals Ltd. QNRX · Entity 7876	GrantShare Option (Right to Buy) · Derivative	50,714	$0.00 Strike: $0.78	$0.00	Disclosure SEC source: 0001104659-24-127240 · tm2430519-6_4seq1.xml · derivative · entry 1 Culverwell Anthony James · CIK 0001693548 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,714 Underlying: ADS · 50,714 shares Expires 2034-12-09 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of December 9, 2025, 2026 and 2027 and 40% vesting on December 9, 2028. F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer. Read SEC document
October 26, 2023 Filed Oct 30, 2023 20:10 UTC	Quoin Pharmaceuticals Ltd. QNRX · Entity 7876	GrantShare Option (Right to Buy) · Derivative	7,652	$0.00 Strike: $5.75	$0.00	Disclosure SEC source: 0001104659-23-112565 · tm2329341-3_4seq1.xml · derivative · entry 1 Culverwell Anthony James · CIK 0001693548 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,652 Underlying: American Depositary Share · 7,652 shares Expires 2033-10-26 F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of October 26, 2024, 2025 and 2026 and 40% vesting on October 26, 2027. F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS. Read SEC document
July 24, 2017 Filed Jul 26, 2017 23:00 UTC	Innocoll Holdings plc INNL · Entity 12261	Disposition to issuerWarrant · Derivative	57,240	Not disclosed Strike: $7.00	Not disclosed	Disclosure SEC source: 0001144204-17-038440 · v471491_4.xml · derivative · entry 5 Culverwell Anthony James · CIK 0001693548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares, par value $0.01 per share · 57,240 shares Expires 2019-06-15 F4 · shares: Immediately prior to the Effective Time, the Reporting Person beneficially owned a warrant to purchase up to 57,240 Ordinary Shares (the "Warrant"). Pursuant to the terms of an Irrevocable Undertaking executed by the Reporting Person in connection with the Transaction Agreement, immediately prior to the Effective Time, the Warrant was terminated without any consideration being payable in respect thereof. F4 · price: Immediately prior to the Effective Time, the Reporting Person beneficially owned a warrant to purchase up to 57,240 Ordinary Shares (the "Warrant"). Pursuant to the terms of an Irrevocable Undertaking executed by the Reporting Person in connection with the Transaction Agreement, immediately prior to the Effective Time, the Warrant was terminated without any consideration being payable in respect thereof. F4 · derivative.exercise_date: Immediately prior to the Effective Time, the Reporting Person beneficially owned a warrant to purchase up to 57,240 Ordinary Shares (the "Warrant"). Pursuant to the terms of an Irrevocable Undertaking executed by the Reporting Person in connection with the Transaction Agreement, immediately prior to the Effective Time, the Warrant was terminated without any consideration being payable in respect thereof. F4 · derivative.underlying_shares: Immediately prior to the Effective Time, the Reporting Person beneficially owned a warrant to purchase up to 57,240 Ordinary Shares (the "Warrant"). Pursuant to the terms of an Irrevocable Undertaking executed by the Reporting Person in connection with the Transaction Agreement, immediately prior to the Effective Time, the Warrant was terminated without any consideration being payable in respect thereof. Read SEC document
July 24, 2017 Filed Jul 26, 2017 23:00 UTC	Innocoll Holdings plc INNL · Entity 12261	Disposition to issuerStock Option (right to buy) · Derivative	14,907	Not disclosed Strike: $8.80	Not disclosed	Disclosure SEC source: 0001144204-17-038440 · v471491_4.xml · derivative · entry 4 Culverwell Anthony James · CIK 0001693548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares, par value $0.01 per share · 14,907 shares Expires 2026-03-30 F3 · shares: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F3 · price: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F3 · derivative.exercise_date: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F3 · derivative.underlying_shares: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. Read SEC document
July 24, 2017 Filed Jul 26, 2017 23:00 UTC	Innocoll Holdings plc INNL · Entity 12261	Disposition to issuerStock Option (right to buy) · Derivative	8,230	Not disclosed Strike: $8.80	Not disclosed	Disclosure SEC source: 0001144204-17-038440 · v471491_4.xml · derivative · entry 3 Culverwell Anthony James · CIK 0001693548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares, par value $0.01 per share · 8,230 shares Expires 2026-03-30 F3 · shares: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F3 · price: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F3 · derivative.exercise_date: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F3 · derivative.underlying_shares: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. Read SEC document
July 24, 2017 Filed Jul 26, 2017 23:00 UTC	Innocoll Holdings plc INNL · Entity 12261	Disposition to issuerStock Option (right to buy) · Derivative	11,659	Not disclosed Strike: $8.80	Not disclosed	Disclosure SEC source: 0001144204-17-038440 · v471491_4.xml · derivative · entry 2 Culverwell Anthony James · CIK 0001693548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares, par value $0.01 per share · 11,659 shares Expires 2026-03-30 F3 · shares: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F3 · price: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F3 · derivative.exercise_date: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F3 · derivative.underlying_shares: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 34,796 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. Read SEC document
July 24, 2017 Filed Jul 26, 2017 23:00 UTC	Innocoll Holdings plc INNL · Entity 12261	Disposition to issuerOrdinary Shares, par value $0.01 per share	291,566	Not disclosed	Not disclosed	Disclosure SEC source: 0001144204-17-038440 · v471491_4.xml · nonDerivative · entry 1 Culverwell Anthony James · CIK 0001693548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Immediately prior to the Effective Time (as defined below), the Reporting Person beneficially owned 291,566 ordinary shares of the Issuer, par value $0.01 per share ("Ordinary Shares"). F2 · price: Pursuant to the terms of the Transaction Agreement by and among the Issuer, Gurnet Point L.P., a Delaware limited partnership acting through its general partner Waypoint International GP LLC ("Gurnet Point"), and Lough Ree Technologies Limited, an Irish private limited company and wholly-owned subsidiary of Gurnet Point (the "Transaction Agreement"), each Ordinary Share that was beneficially owned by the Reporting Person immediately prior to the effective time of the scheme (the "Effective Time") now represents the right to receive (i) $1.75 in cash and (ii) a contingent value right which represents a contractual right to receive payments up to a maximum aggregate amount of $4.90 in cash upon, and subject to, the occurrence of certain events, without interest and net of applicable tax withholdings. F2 · balance_after: Pursuant to the terms of the Transaction Agreement by and among the Issuer, Gurnet Point L.P., a Delaware limited partnership acting through its general partner Waypoint International GP LLC ("Gurnet Point"), and Lough Ree Technologies Limited, an Irish private limited company and wholly-owned subsidiary of Gurnet Point (the "Transaction Agreement"), each Ordinary Share that was beneficially owned by the Reporting Person immediately prior to the effective time of the scheme (the "Effective Time") now represents the right to receive (i) $1.75 in cash and (ii) a contingent value right which represents a contractual right to receive payments up to a maximum aggregate amount of $4.90 in cash upon, and subject to, the occurrence of certain events, without interest and net of applicable tax withholdings. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.